Michele Hutchison
Pediatric Endocrinology · Albuquerque, NMNPI 1346201639
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (40.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Biomarin Pharmaceutical Inc. accounts for 66.4% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $5,284 and has fallen 85.4% since, to $769 in 2025.
Across 62 payments — averaging $123.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$5K
- Insulet Corporation$729
- Kyowa Kirin, Inc.$360
- Medtronic$247
- Abbott$243
- Ultragenyx Pharmaceutical Inc.$227
- plus $771 from 13 others
Across 60 payments — averaging $2252.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$62K
- Takeda Pharmaceuticals U.S.A., Inc.$46K
- Eli Lilly$14K
- Novo Nordisk Health Care AG$13K
What the payments were for
- Speaking & faculty fees$3,00039%
- Travel & lodging$1,48719%
- Food & beverage$3,07540%
- Education$951%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 14 | $5,081 |
| Insulet Corporation | 13 | $729 |
| Kyowa Kirin, Inc. | 4 | $360 |
| Medtronic(2 entities) | 6 | $247 |
| Abbott | 3 | $243 |
| Ultragenyx Pharmaceutical Inc. | 3 | $227 |
| Ascendis Pharma Endocrinology Inc | 1 | $122 |
| Sanofi-aventis U.S. LLC | 1 | $122 |
| Novo Nordisk | 3 | $104 |
| Pfizer | 1 | $98 |
| Tandem Diabetes Care, Inc. | 3 | $91 |
| Tolmar Pharmaceuticals, Inc. | 1 | $58 |
| Dexcom, Inc. | 2 | $46 |
| AbbVie | 2 | $32 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| BETA Bionics, Inc. | 1 | $22 |
| Tolmar, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$488
- CRYSVITA$125
- FREESTYLE LIBRE 3$124
- SKYTROFA$122
- TZIELD$122
- MINIMED 780G$113
How this compares
Too few pediatric endocrinology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.
Other pediatric endocrinology in Albuquerque
- Alicia MarksAlbuquerque$4K
- Maria HizonAlbuquerque$2K
- Swashti AgarwalAlbuquerque$1K
- Michael YaoAlbuquerque$1K
- Kathryn GadomskiAlbuquerque$87
- Susan ScottAlbuquerque$23
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.